A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis.

Abstract

BACKGROUND:

Progressive multiple sclerosis (PMS) is a debilitating condition characterized by progressively worsening symptoms. Monoclonal antibodies are novel therapies for MS, but their safety and efficacy in the progressive form have not been comprehensively studied. In this systematic review, we aimed to evaluate the available evidence regarding monoclonal antibody treatment for PMS.

METHODS:

After registration of the study protocol in PROSPERO, we systematically searched three major databases for clinical trials involving monoclonal antibodies administration for PMS treatment. All the retrieved results were imported into the EndNote reference manager. After removing the duplicates, two independent researchers did the study selection and data extraction. The risk of bias was assessed using the Joanna Briggs Institute (JBI) checklist.

RESULTS:

Of the 1846 studies in the preliminary search, 13 clinical trials investigating monoclonal antibodies (Ocrelizumab, Natalizumab, Rituximab, and Alemtuzumab) in PMS patients were included. Ocrelizumab was significantly effective in reducing clinical disease progression measures in primary PMS patients. The results for Rituximab were not completely reassuring and only showed significant changes for some endpoints on MRI and clinical measures. Natalizumab decreased the relapse rate and improved MRI features for secondary PMS patients, but not clinical endpoints. The studies on Alemtuzumab treatment revealed conflicting outcomes, with improvements observed in MRI endpoints but clinical worsening in patients. Additionally, among the studied adverse events, upper respiratory infections, urinary tract infections, and nasopharyngitis were frequently reported.

CONCLUSION:

Based on our findings, Ocrelizumab is the most efficient monoclonal antibody for primary PMS, although it is associated with a higher risk of infection. While other monoclonal antibodies did not show significant promise in treating PMS, more research is necessary.

• Authors: Zahra Sabahi, Amin Daei Sorkhabi, Aila Sarkesh, Amirreza Naseri, Nazli Asghar-Rezaei, Mahnaz Talebi
• Journal: International immunopharmacology (Int Immunopharmacol) Vol. 120 Pg. 110266 (Jul 2023) ISSN: 1878-1705 [Electronic] Netherlands
• PMID: 37209514 (Publication Type: Systematic Review, Journal Article, Review)
• Copyright: Copyright © 2023 Elsevier B.V. All rights reserved.

Chemical References

• Antibodies, Monoclonal
• Rituximab
• Natalizumab
• Alemtuzumab

Topics

• Humans
• Antibodies, Monoclonal (adverse effects)
• Rituximab (therapeutic use)
• Natalizumab (therapeutic use)
• Alemtuzumab
• Multiple Sclerosis (drug therapy)
• Multiple Sclerosis, Relapsing-Remitting (drug therapy)